- Home
- GLUE vs NVRI Comparison
GLUE vs NVRI Comparison
Compare GLUE & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | NVRI |
|---|---|---|
| Founded | 2019 | 1853 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GLUE | NVRI |
|---|---|---|
| Price | $23.69 | $22.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 472.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,672,000.00 | N/A |
| Revenue This Year | N/A | $3.87 |
| Revenue Next Year | $2.45 | $3.70 |
| P/E Ratio | $72.42 | ★ N/A |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $4.12 | $7.70 |
| 52 Week High | $25.77 | $23.56 |
Technical Indicators
Market Signals| Indicator | GLUE | NVRI |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | 57.22 |
| Support Level | $17.35 | $17.79 |
| Resistance Level | $25.56 | N/A |
| Average True Range (ATR) | 1.57 | 1.09 |
| MACD | 0.37 | 0.06 |
| Stochastic Oscillator | 78.95 | 67.48 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.